论文信息 - A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. - 字舞流文

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

H. Mo | G. Cheng | T. Marbury | A. Mathias | D. Brainard | J. McHutchison | E. Lawitz | J. Link | D. Gruener | Kelly A. Wong | L. Moorehead | John M. Hill | K. A. Wong | J. Hill | J. Mchutchison